Specify a stock or a cryptocurrency in the search bar to get a summary
Suzhou Zelgen Biopharmaceuticals Co Ltd
688266Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China. Address: No. 209, Chenfeng Road, Kunshan, China, 215300
Analytics
WallStreet Target Price
419.49 CNYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 688266
Dividend Analytics 688266
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 688266
Stock Valuation 688266
Financials 688266
Results | 2019 | Dynamics |